Vaxart (OTCMKTS:VXRT) Announces Earnings Results

Vaxart (OTCMKTS:VXRT) announced its quarterly earnings results on Thursday. The biotechnology company reported $0.02 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.02, Zacks reports. Vaxart had a return on equity of 75.49% and a net margin of 14.51%.The firm had revenue of $39.23 million for the quarter, compared to analysts’ expectations of $65.50 million.

Vaxart Price Performance

VXRT traded down $0.04 during midday trading on Friday, reaching $0.70. 691,277 shares of the company’s stock traded hands, compared to its average volume of 433,090. The firm has a fifty day moving average of $0.70 and a two-hundred day moving average of $0.54. The stock has a market capitalization of $169.38 million, a price-to-earnings ratio of 4.67 and a beta of 1.18. Vaxart has a 52 week low of $0.26 and a 52 week high of $0.84.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Vaxart to a “buy” rating in a report on Friday, January 23rd.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. bought a new stake in shares of Vaxart in the first quarter worth about $31,000. Creative Planning purchased a new stake in Vaxart during the second quarter worth $33,000. Invesco Ltd. increased its position in shares of Vaxart by 93.1% during the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 70,568 shares in the last quarter. Raymond James Financial Inc. increased its position in shares of Vaxart by 16.9% during the second quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock worth $107,000 after purchasing an additional 34,075 shares in the last quarter. Finally, Jones Financial Companies Lllp increased its position in shares of Vaxart by 276,364.7% in the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after acquiring an additional 478,111 shares during the period. Institutional investors own 18.05% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.